NEW YORK — Qure.ai has appointed Dr. Javier J. Zulueta, a leading pulmonologist and academic, as its new Chief Medical Officer for Pulmonology. The move is aimed at accelerating the company’s clinical strategy in lung health and expanding its AI-powered solutions in the U.S. and Europe.
Zulueta, formerly a professor of medicine at the Icahn School of Medicine at Mount Sinai and Pulmonary Division Chief at Mount Sinai Morningside Hospital, brings more than three decades of experience in interventional pulmonology, lung cancer screening, and pulmonary disease management. He previously founded the Department of Respiratory Medicine at Clinica Universidad de Navarra, Spain’s premier medical school, where he led the country’s first lung cancer screening program as part of the International Early Lung Cancer Action Program (IELCAP).
“We warmly welcome Dr. Zulueta to bring his unmatched global expertise in lung cancer screening and management to Qure.ai,” said Prashant Warier, founder and CEO of Qure.ai. “His knowledge will be instrumental in the ongoing strategic development of our Lung Cancer Suite of AI-powered solutions and to drive clinical deployments in health systems and hospitals at scale.”
Zulueta said he views the role as a chance to combine clinical expertise with emerging AI technology to make a generational impact. “Lung cancer remains the deadliest cancer in the world, not because we can’t treat it, but because we find it too late,” he said. “We stand at a pivotal moment in clinical and technology disruption where the power of AI can be harnessed safely to turn small incidental lung nodule findings into lifesaving interventions. Joining Qure.ai puts me at the epicentre of this change – we have the potential to change the survival curve in a single generation.”
The appointment comes as Qure.ai continues to expand its footprint in the U.S. Earlier this year, the company hired Jim Mercadante as Chief Commercial Officer and added a dozen sales and strategy executives. In 2025, Qure.ai was recognized as one of TIME100’s Most Influential Companies for its use of AI in diagnosing high-burden diseases. The company’s technology is currently deployed in more than 100 countries and holds 18 FDA-cleared findings.
